Saturday 17 October 2026
Export SNTI’s income statement to Excel — free account
Senti Biosciences, Inc.
SNTI Healthcare Biotechnology
Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023. In the quarter to June 2026, revenue fell 98.7%, EPS grew 26.8% and free cash flow fell 7.48%, each against the same quarter a year earlier.
0.22
0.04
−15.38%
Follow SNTI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '17 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 2 | — | — | — |
P/E ratio |
0.00 | — | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(13.71) | — | (4.48) | (1.48) | (2.37) | — |
P/S ratio |
8.93 | — | 11.20 | 9.02 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(30.52) | — | (7.33) | 0.13 | (4.16) | — |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | 38.49 | (2.40) | — | — |
P/Operating CF |
(3.40) | — | (4.17) | (4.29) | (2.40) | — |
P/B ratio |
4.18 | — | 0.44 | 0.30 | 0.00 | — |
Price to Tangible BV |
4.18 | — | 0.44 | 0.30 | 0.00 | — |
EV/Sales |
2.67 | — | (2.46) | (13.95) | 0.00 | — |
EV/EBITDA |
0.00 | — | 0.07 | 1.03 | 0.69 | — |
EV/Operating CF |
(0.16) | — | 0.12 | 1.71 | 0.77 | — |
EV/FCF |
(0.16) | — | 0.10 | 0.78 | 0.77 | — |
Quick Ratio |
1.29 | 3.81 | 4.23 | 5.49 | 3.89 | — |
Current Ratio |
1.67 | 4.49 | 5.62 | 5.68 | 4.14 | — |
Net Debt/EBITDA |
0.25 | 0.84 | 0.41 | 1.69 | 1.48 | — |
Debt/Assets |
0.00% | 0.01% | 0.11% | 0.07% | 0.65% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | (0.01) | — |
Asset Turnover |
0.00 | 0.00 | 0.02 | 0.03 | 0.06 | — |
Operating CF/Net income |
0.71 | 0.78 | 0.74 | 0.60 | 0.63 | — |
Capex/Depreciation |
(0.05) | 0.01 | (2.20) | (10.55) | (1.84) | — |
| (393.35%) | (114.06%) | (73.19%) | (736.56%) | 0.00% | — | |
| (82.43%) | (48.58%) | (47.33%) | (41.95%) | (114.41%) | — | |
ROIC |
0.00% | 0.00% | (186.22%) | (134.57%) | 0.00% | — |
Return on Tangible Assets |
(276.92%) | (78.67%) | (84.73%) | (42.84%) | (95.35%) | — |
Average Days of Receivables |
26,462.50 | 0.00 | 2,523.22 | 53.31 | 63.85 | — |
Research and Development Expense of Revenue |
170,845.45% | 0.00% | 1,255.37% | 656.67% | 795.26% | — |
Selling, General and Administrative Expense of Revenue |
118,922.73% | 0.00% | 1,451.62% | 891.86% | 769.65% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
25,936.36% | 0.00% | 377.59% | 382.45% | 83.12% | — |
Graham Net Nets |
(0.96) | — | 0.64 | 1.27 | (5.15) | — |
Graham Number |
0.00 | — | 0.00 | 0.00 | 1,279.06 | — |
Earnings Yield |
(306.73%) | — | (242.06%) | (363.77%) | (192.67%) | — |
Free Cash Flow Yield |
(186.63%) | — | (219.34%) | (197.36%) | (120.63%) | — |
Revenue per Share |
0.00 | 0.00 | 0.58 | 1.64 | 9.48 | — |
Operating CF per Share |
(1.93) | (9.01) | (11.81) | (13.36) | (118.94) | — |
Capex per Share |
(0.01) | 0.01 | (2.69) | (15.85) | (19.03) | — |
Free Cash Flow per Share |
(1.94) | (9.00) | (14.50) | (29.21) | (137.97) | — |
Cash per Share |
0.73 | 10.50 | 8.10 | 37.75 | 192.42 | — |
Shareholders Equity per Share |
0.25 | 5.58 | 15.08 | 48.74 | (382.75) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.25 | 5.58 | 15.08 | 48.74 | (382.75) | — |
Free Cash Flow |
(43.63) | (41.36) | (64.33) | (76.27) | (40.18) | — |
Working Capital |
9.30 | 45.82 | 58.53 | 84.53 | 45.65 | — |
Capital Expenditures |
(0.18) | 0.03 | (11.93) | (41.37) | (5.54) | — |
Net Current Asset Value |
(22.36) | (13.23) | 18.63 | 49.05 | (147.97) | — |
EV/EBIT |
0.00 | — | 0.07 | 0.96 | 0.66 | — |
Capex to Sales |
8.36 | 0.00 | 4.66 | 9.65 | 2.01 | — |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||
Depreciation/Fixed assets |
0.28 | 0.18 | 0.21 | 0.08 | 0.24 | — |
Cash ROIC |
(198.23%) | (55.94%) | (62.47%) | (33.75%) | 73.32% | — |
Accounts Receivable Turnover |
0.01 | 0.00 | 0.28 | 7.73 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
1.70 | 9.75 | 9.17 | 0.55 | — | — |
Average Payables |
2.20 | 1.35 | 1.31 | 3.28 | — | — |
Average Assets |
74.53 | 108.66 | 150.14 | 138.75 | 48.35 | — |
Average Common Equity |
15.62 | 46.28 | 97.09 | 7.90 | — | — |
Columns are period end dates